Navigation Links
Dendreon Announces Election of Dr. David C. Stump to Board of Directors
Date:6/2/2010

t.  Dr. Stump received his M.D. from Indiana University and his bachelor's degree from Earlham College.  He completed his residency and fellowship training in internal medicine, hematology, and oncology at the University of Iowa and is board certified in all three areas.  He is currently a member of the Board of Directors for Sunesis Pharmaceuticals, Inc. as well as of the Boards of Trustees for Adventist HealthCare, Inc. and for Earlham College.

About Dendreon

Dendreon Corporation is a biotechnology company targeting cancer and transforming lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first active cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... RENU 28, the world's first and only skin ... purchase in Australia and New Zealand in mid-August . , ... The tour will make stops in Brisbane on September 16, ... Sydney on the 20th, and Melbourne on the 22nd. , ... and to educate people about the new product and business ...
(Date:9/15/2014)... 2014 Cancer Immunotherapy Market ... T-cell Therapies is a new market research report ... three principal types of therapeutics that have become ... cancer immunotherapy (which is often called "immuno-oncology") in ... Adoptive cellular immunotherapy. , The regular use ...
(Date:9/15/2014)... developed a technique for controlling the surface tension of ... door to a new generation of reconfigurable electronic circuits, ... fact that the oxide "skin" of the metal ... a surfactant, lowering the surface tension between the metal ... liquid metal alloy of gallium and indium. In base, ...
(Date:9/15/2014)... Northeastern University has developed a novel method for ... of nanocarbon structures in carbon nanotube arrays. The ... allow the researchers to tailor the physical properties ... from electronic devices to CNT-reinforced composite materials found ... Their findings were published in the journal ...
Breaking Biology Technology:Global Wellness Company Hosts ASEA Australia Tour September 16-22 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5Researchers control surface tension to manipulate liquid metals 2Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Pa. , Feb. 2 Fibrocell Science, ... on the development of regenerative cell therapy for aesthetic, ... Pernock , Chairman of the Board of Directors, has ... most recently served as Senior Vice President (SVP), Pharmaceuticals, ...
... , LIVERPOOL, February 2 ... Cambian healthcare Noel Tracey to lead its,expanding Community ... Noel has more than 15 years, experience of senior management ... In his previous role as,director of operations at Cambian Healthcare, ...
... ... the life of the International Space Station (ISS) to 2020 or beyond. , ... (Vocus) February 1, 2010 -- Astrogenetix is ... Station (ISS) to 2020 or beyond. , ,Thomas B. Pickens III, Chairman of Astrogenetix, Inc.:, ...
Cached Biology Technology:Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 2Fibrocell Science, Inc. Names David Pernock Chief Executive Officer 3Noel Tracey to Head Up Gray Healthcare Recovery Team 2Astrogenetix Statement On Nasa's Fiscal Year 2011 Budget Announcement 2
(Date:9/16/2014)... , Sept. 16, 2014  Cross Match ... management solutions, announced today the launch of its ... authenticate the identity of an individual using their ... Verifier Sentry rapidly reads credential documents with embedded ... by matching the biometric to a live scan ...
(Date:9/15/2014)... 15, 2014) The so-called central dogma of ... long provided a simplified explanation for how genetic ... , In reality, of course, the process ... articulated nearly 60 years ago by Nobel Laureate ... For one, there are multiple types of RNA, ...
(Date:9/15/2014)... research has determined that a single group of microorganisms ... B12 production in the oceans, with implications for the ... B12 is an essential molecule required by most life ... relatively small group of microorganisms because it is so ... key role in maintaining the brain and nervous systems, ...
Breaking Biology News(10 mins):Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2Researchers discover new producer of crucial vitamin 2
... application of biosolids (treated municipal sewage sludge) is a ... plant nutrients and organic matter. However, the presence of ... that farmland application may result in accumulation of dioxins ... food chain because several congeners of dioxins have extremely ...
... remotely piloted aircraft carrying a NASA sensor flew over ... will be used to help fight more than 300 ... for next week. The flights by NASA,s ... Scanner developed at NASA,s Ames Research Center at Moffett ...
... In one of the first studies to link ... published in the August issue of the ... serious and violent delinquencythat gain predictive precision when ... friends and school processes. Sociologists from the ...
Cached Biology News:Dioxin risk in soil and plant tissues after long-term biosolids application 2NASA responds to California wildfire emergency imaging request 2NASA responds to California wildfire emergency imaging request 3Sociological research shows combined impact of genetics, social factors on delinquency 2
...
Request Info...
Request Info...
... KingFisher magnetic particle based purification systems provide ... from any sample. They offer increased throughput ... three systems- KingFisher, KingFisher mL and KingFisher ... 1000 l. Each system consists of an ...
Biology Products: